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Abstract  
This study aims to characterize alexithymia in a sample of women with breast cancer and to 
analyze the relationship of alexithymia with quality of life perception and with a set of 
disease specific symptoms from the Quality of Life Questionnaire (QLQC-30) and Breast 
Cancer Module (QLQ-BR23). Our sample consists of 85 women with breast cancer that are 
receiving treatment in a hospital in Porto, with a mean age of 47 years (M = 46.99, SD = 
7.39). In clinical terms, 44.7% of the sample is between the 2nd and 6th month after cancer 
diagnosis, 63.5% went through a total mastectomy and 89.4% are going through or have 
already finished chemotherapy. The results show that women in our sample are significantly 
more alexithymic than the regular population and that the presence of alexithymia seems to 
hinder the adjustment to the disease, since it is associated with worse perceptions on the 
functional scales, greater perceptions of physical symptoms and side effects from anticancer 
treatments. 
Keywords: breast cancer, alexithymia, quality of life  
 
Resumo 
Este estudo pretende caraterizar a alexitimia numa amostra de mulheres com cancro de mama 
e analisar a relação da alexitimia com a perceção de qualidade de vida e com os sintomas 
físicos relacionados com a doença, do Quality of Life Questionnaire (QLQC-30) e do Breast 
Cancer Module (QLQ-BR23), instrumentos utilizados para este estudo. A amostra é 
constituída por 85 mulheres com cancro de mama utentes de um Hospital do Porto, com uma 
média de 47 anos (M=46.99, DP=7.39). Em termos clínicos, 44.7% da amostra encontra-se 
entre o 2º e o 6º mês após o diagnóstico de cancro de mama, 63.5% realizou mastectomia 
total e 89.4% encontra-se a realizar ou já realizou quimioterapia. Os resultados encontrados 
demonstram que as mulheres com cancro de mama da nossa amostra são significativamente 
mais alexitimicas do que as mulheres da população normativa e que a presença da alexitimia 
na nossa amostra parece prejudicar a adaptação à doença, uma vez que está associada a 
perceções mais negativas sobre as escalas de funcionamento, a uma maior perceção sobre a 
presença de sintomas físicos e efeitos colaterais associados aos tratamentos antineoplásicos.  




                                                                                             ALEXITHYMIA IN BREAST CANCER      63 
   
 
ORIGINAL      
Introduction 
Breast cancer is the malignancy 
that most affects the female population. 
It’s estimated that, over a lifetime, one in 
nine women will develop this disease 
(Fernandez-Delgado et al., 2008). Studies 
on this condition have registered a 
significant increase in incidence, but cases 
of death have been declining in recent 
decades. Due to technological 
advancements in medical sciences, we are 
witnessing a growing optimism regarding 
the treatment of cancer and increased 
survival rates of about 84% within 5 years 
after treatment (Brenner & Hakulinen, 
2006). 
 Nevertheless, breast cancer 
continues to be an adverse and potentially 
traumatic life-event, with treatments that 
are usually prolonged and uncertain, 
accompanied by high biopsychosocial and 
spiritual needs, with a deep and lasting 
impact in quality of life (Montarezi, 2007). 
In order to better identify the 
factors that may interfere with the risk of 
psychosocial dysfunction in this 
population, it’s important to know the 
variables that may put at risk and/or 
protect the quality of life of these women 
(Silva, Bettencourt, Moreira, & Canavarro, 
2011).  
The importance of emotional 
expression and its consequences on a 
physical and psychological level has been 
increasingly studied by health psychology, 
because of its critical role in diseases 
(Fonte, 1993), including cancer (Graves et 
al., 2005). The study of alexithymia or “no 
words for feelings” (Fernandes & Tomé, 
2002, p.97),  arises in this context as a 
maladaptive coping mechanism (Iwamitsu 
et al., 2003) that has been shown to have a 
negative correlation with some dimensions 
included in the quality of life concept 
(Gritti et al, 2010; Shibata et al, 2014). 
 
Alexithymia 
Alexithymia is defined as the 
difficulty to recognize and express 
emotions (Manna et al., 2007). 
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Theoretically, alexithymics are described 
as individuals who demonstrate emotional 
difficulties, since they (1) fail to describe 
their emotions and feelings, (2) have 
difficulties dissociating emotions from 
bodily sensations, (3) trouble perceiving 
emotional states and desires of others, (4) 
expressionless and introverted behavior 
and (5) low capacity for empathy (Fonte, 
1993).  
There are different perspectives on 
the role of alexithymia in cancer, since it 
can be considered primary or secondary to 
the disease (Sifneos, 1991; Taylor, Parker, 
Bagby, & Acklin, 1992). Alexithymia is 
conceptualized as either a stable 
personality trait or a defensive reaction and 
a coping mechanism in response to 
stressful events (Gritti et al., 2010). In 
these hypotheses alexithymia could, 
alternatively, be considered as a health risk 
factor or as a consequence of the 
emotional struggle that comes with facing 
cancer, working, in both cases, as a 
predictor of treatment outcome.   
According to the first hypothesis, 
alexithymia has been regarded as a 
vulnerability factor (Vries, Forni, 
Voellinger, & Stiefel, 2012). Several 
studies have indicated alexithymia as a 
stable Type C Personality trait (Sifneos, 
1991; Taylor, 1992; Vazquez et al, 2003). 
By contrast, some studies define 
alexithymia as a coping strategy secondary 
to certain traumatic events, taking place as 
a defense mechanism against the intense 
emotion that comes with a serious disease. 
Thus, it would be a transitory state, 
softening up after remission (Fernandes & 
Tomé, 2001; Graves et al., 2005). This 
theory that alexithymia would decrease 
with survival is consistent with studies of 
the possibility of a post-traumatic growth 
and self-discovery that, in turn, would 
provide better emotional expression 
(Graves et al., 2005). 
In both cases, being a personality 
trait or a coping mechanism secondary to 
cancer, studies seem to indicate that 
alexithymia impairs quality of life, since it 
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is a strong indication of a repressive 
coping mechanism and, therefore, 
maladaptive to the cancer process 
(Iwamitsu et al., 2003). Moreover, a good 
emotional expression seems to be 
associated with a higher psychosocial 
well-being, increased confidence and 
assertiveness, a better fighting spirit and an 
improved quality of life (Lieberman & 
Goldstein, 2006; Mantani et al., 2007). 
Alexithymia is also hypothesized to 
be an important factor in the development 
of medically unexplained physical 
symptoms (Gritti et al., 2010). The 
association between alexithymia and 
cancer is still unclear and controversial. 
The investigation of this variable in 
chronic illnesses such as cancer, highlights 
intriguing issues regarding the nature and 
the role of this construct. Some studies 
have detected high alexithymia rates in 
cancer patients compared to healthy 
controls. Manna et al. (2007) compared a 
group of women with breast cancer with a 
control group (women without the 
disease), concluding that women with 
breast cancer are significantly more 
alexithymic. Watson, Pettingale and Greer 
(1984, as cited in Graves et al., 2005) also 
show that women with this condition tend 
to respect social norms, intend to be seen 
as good people and have a strong tendency 
to deny, suppress or internalize their 
feelings. In Portugal, we found only one 
study by Guerra, Pinto and Mariano 
(2007), indicating a prevalence of 
alexithymia in women with breast cancer 
two times higher than the regular 
population. No significant differences 
were found on a sociodemographic level or 
by type of treatment (whether surgical or 
adjuvant), so the authors raise the 
hypothesis that distress induced by the 
disease, has such a magnitude, that it may 
cause alexitimia by itself.  
However, the role of alexithymia in 
cancer patients seems to be more complex 
and requires further investigation. 
 
Quality of life 
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A breast cancer diagnosis presents 
different challenges for women (Holland 
& Holahan, 2003). As a chronical disease, 
it seems to affect and modify multiple 
domains of quality of life with 
consequences that can last for years (Pinto 
& Ribeiro, 2006).  
There are different definitions of 
the concept of quality of life. In 1993, the 
World Health Organization proposed a 
definition that considers "the perception of 
the individual about their position in life, 
in the context of their culture and their 
value systems, in relation to their goals, 
expectations, standards and concerns 
"(WHOQOL Group, 1994, 1995, as cited 
in Paredes et al, 2008, p 74; Pimentel, 
2006). 
Due to a growing interest in the 
study of quality of life within the 
framework of the disease, the term "quality 
of life related to health" emerges 
(Pimentel, 2006, p.25). This concept 
represents the individual responses to the 
effects of the disease (Costa et al, 2013), 
comprising a multidimensional perspective 
that includes physical, psychological, 
social and spiritual dimensions, as well as 
the evaluation of health services (Pimentel, 
2006; Pinto & Ribeiro, 2006). 
In oncology setting, studies 
evaluating the quality of life in cancer 
patients have come to different 
conclusions. Some authors advocate the 
importance of evaluating this variable in 
breast cancer, as this disease is 
characterized by an incidence in the female 
population and it is associated with a wide 
range of biopsychosocial consequences, 
such as on a working level (chemobrain, 
difficulties moving the upper limbs 
affected by the disease), on a social and 
family level (sexual life, fertility issues) 
and on a personal level (self-image, self-
esteem) (Holland & Holahan, 2003; 
Safarinejad, Shafi, & Safarinejad, 2013). 
Other studies report that the quality of life 
of women with breast cancer is better than 
expected (Lopes Ribeiro, & Leal, 1999).  
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Recent Portuguese studies show 
that women with breast cancer have a 
moderately positive perception of their 
quality of life (Rebelo, Rolim, Carqueja, & 
Ferreira, 2007). This seems to suggest that 
cancer may affect a woman's quality of life 
less than what is generally expected and 
that, despite the fact that breast cancer is a 
potentially traumatic life-event, patients 
tend to show normal operating standards, 
which can be an important indicator of 
their resilience (Knobf, 2007). 
 
Alexithymia and quality of life in 
oncology 
Studies that focused on 
dispositional tendencies to suppress 
emotions, have been associating this trait 
with poorer adjustment to the cancer 
experience, indicating that it has a negative 
relationship with physical and 
psychological health (Classen, Koopman, 
Angell & Spiegel, 1996; Watson, Greer, & 
Rowden, 1991).  
Research points to several 
mechanisms through which emotional 
suppression may influence symptom 
experiences and well-being during cancer 
treatments (Schlatter & Cameron, 2010). 
On the one hand, alexithymics may be 
motivated to hide their experiences and 
under-report side effects of treatment in 
the attempt to be brave and to minimize 
the distress of their caregivers. On the 
other hand, emotional difficulties may 
exacerbate and predict the severity and 
perception of specific symptoms like 
fatigue (Gritti et al., 2010), constipation, 
pain (Porcelli et al., 2007; Shibata et al., 
2014), nausea and vomiting (Ashkhaneh et 
al., 2015). Studies seem to be more 
consistent on this last hypothesis, showing 
that alexithymia is related to higher levels 
of cancer-related worries and to a poorer 
quality of life (Grassi, Rossi, Sabato, 
Cruciani, & Zambelli, 2004). The 
physiological effect of alexithymia seems 
to enhance stress-related action of 
hypothalamic–pituitary–adrenocortical 
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(HPA) processes and, therefore, it might 
increase the experience of autonomic and 
immune-related symptoms during 
treatments (Schlatter & Cameron, 2010).  
However, the majority of the 
research found on this subject is focused 
on demonstrating the relation between 
emotional difficulties by measuring 
anxiety, depression and anger and studying 
its association with quality of life. Very 
few studies have evaluated alexithymia 
and its impact on cancer symptoms and 
treatments side effects with relation to 
quality of life perceptions (Grassi, Caruso, 
& Nanni, 2013). Although one of the 
major challenges of the cancer experience 
is coping with treatment and its 
symptomatic side effects, research also 
seems to focus on a limited set of 
chemotherapy side effects like fatigue, 
pain, nausea and vomiting. Consequently, 
Grassi et al. (2013) point to the need of 
more research aiming to evaluate the 
prevalence of alexithymia in oncology 
settings, while considering a more 
dimensional inclusive approach and other 
clinically relevant symptoms.  
Taking that into consideration and, 
to our knowledge, this is the first research 
that aims to study the role of alexithymia 
in the quality of life of women with breast 
cancer, evaluating its impact on a new set 
of symptoms, usually reported by patients 
while undergoing treatment.  
 
Objectives 
This study has two main objectives. 
The first, is to characterize alexithymia in 
our sample of women with breast cancer, 
considering the lack of research on this 
variable in clinical populations. The 
second aim of this study, is to analyze the 
relation of alexithymia with quality of life 
perceptions and, also, with the most 
reported disease specific symptoms. In 
order to accomplish this goal, we have 
selected the European Organization for 
Research and Treatment of Cancer Quality 
of Life Questionnaire (QLQC-30) and 
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Breast Cancer Module (QLQ-BR23). This 
instruments aim to evaluate the patients’ 
quality of life perceptions and to assess the 
presence of a wide range of clinical 
relevant symptoms, currently associated 
with the disease (see Instruments section 
for a more detailed description).  
Methods 
Participants 
Our sample consists of 85 women 
with breast cancer that are receiving 
treatment in a hospital in Porto (Portugal). 
It’s a non - probabilistic convenience 
sample, selected based on the patients 
availability and willingness to participate. 
Despite the fact that non-probabilistic 
samples present some limitations, like the 
lack of representativeness regarding the 
population and the impossibility of 
generalizing the results, in this case, this 
method was the only one possible. These 
methodology was chosen considering that 
studies with this population are difficult to 
accomplish due to ethic motives, the 
disease and treatments side effects, 
prolonged hospitalizations and impact on 
well-being.    
The mean age is 47 years (M = 
46.99, SD = 7.39) and the mean education 
is 10 and a half years (M = 10.45, SD = 
5.47). They are mostly married (76.5%) 
and with children (71.8%). In clinical 
terms, 44.7% of the sample is between the 
2nd and 6th month after the diagnosis, 
63.5% went through a total mastectomy 
and 89.4% is going through or has already 
finished chemotherapy.  
 
Instruments 
For data collection, we used four 
self-report instruments. The 
Sociodemographic and Clinical 
Questionnaire includes two sections, the 
first on sociodemographic data and the 
second on the clinical characteristics of the 
sample. 
The Toronto Alexithymia Scale 
(TAS-20), is the most commonly used tool 
to evaluate the cognitive and affective 
deficits of alexithymia. It’s a 5-point Likert 
                                                                                             ALEXITHYMIA IN BREAST CANCER      70 
   
 
ORIGINAL      
scale with 20 items. The results are 
obtained through the sum of all responses 
and may vary between 20 and 80. 
Individuals with scores higher or equal to 
61 are considered alexithymic, while 
scores lower or equal to 51 are non 
alexithymic. The results scored between 52 
and 60 (included), correspond to a “border 
zone”.  
The original version - "Toronto 
Alexithymia Scale (TAS-20)" - was 
developed by Taylor, Ryan and Bagby. In 
this study, we used the Portuguese version 
from Prazeres, Parker, & Taylor (2000). 
After the translation process, the authors 
demonstrated a cross-linguistic 
equivalence between the original and the 
Portuguese version, applying both versions 
in a non-clinical sample of bilingual 
subjects (r = .91, p <.001). The internal 
consistency of the complete instrument, 
reveals good psychometric qualities with a 
Cronbach’s alpha coefficient of .79 in both 
samples. In terms of stability, this 
Portuguese version showed an excellent 
accuracy test-retest for three weeks (r = 
.90, p <.001) and for a six weeks interval 
(r = .86, p <.001). Overall, these results 
support the use of the TAS-20 as an 
instrument to evaluate alexithymia in our 
population (Prazeres et al., 1998). No 
studies were found using this instrument in 
clinical samples. 
The European Organization for 
Research and Treatment of Cancer Quality 
of Life Questionnaire (QLQC-30, v. 3.0) is 
an internationally used instrument, with 30 
items that assess quality of life in cancer 
patients. It is a questionnaire used or 
considered appropriate for use with cancer 
patients from the moment of diagnosis to 
long survivorship (Aaronsonet al., 1993). 
It is composed by a global quality of life 
subscale; 5 functional subscales (physical, 
role, cognitive, emotional, and social); 3 
symptom subscales (fatigue, pain, and 
nausea/vomiting); and single items for the 
assessment of additional symptoms 
commonly reported by cancer patients 
(dyspnoea, appetite loss, sleep disturbance, 
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constipation, and diarrhoea); one more 
item related to the perceived financial 
impact of cancer and cancer treatment. All 
items are ranged in a 4-point Likert scale 
(1 = None; 4 = Very), except 2 items (29 
and 30) that are filled on a 1 to 7 scale (1 = 
Poor; 7 = Great). All of the scales and 
single item scales range in score from 0 to 
100, obtained by specific algorithms. 
Higher scores for functional scales and 
global quality of life represent 
higher/healthy level of functioning and 
quality of life. However, higher score for a 
symptom scale/item represents a higher 
level of symptomatology or problems. 
This questionnaire was designed 
and structured for international use, being 
currently translated and validated in 38 
languages. Study of the Portuguese version 
metric properties was conducted by Pais-
Ribeiro, Pinto and Santos (2008). The 
authors used a heterogeneous cancer 
patient sample of 933 subjects, with at 
least one month after diagnosis of cancer 
until 31 years after diagnosis. 294 subjects 
of this sample were women with breast 
cancer.  
The study of reliability through 
Cronbach alpha shows an appropriate 
internal consistency for multi item 
functional and symptom scales, with 
values ranging from .57 to .88. When 
comparing the Portuguese version with the 
original and with other versions from 
different languages and cultures (Japanese, 
Turkish, Chinese and Spanish), the authors 
found comparable values, suggesting an 
adequate functional equivalence of the 
questionnaire across languages and 
cultures. A retest for 274 patients was 
conducted six months after the first 
evaluation, and for functional dimensions 
the values are, 0.31, 0.16, 0.28, 0.06, and 
0.19, respectively for physical functioning, 
role functioning, cognitive functioning, 
social functioning, and global quality of 
life. For symptom scales values are, 0.35, 
0.21, 0.39, 0.35, 0.29, 0.38, 0.32 and 0.21, 
respectively for, fatigue, nausea and 
vomiting, pain, dyspnea, appetite loss, 
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sleep, constipation, diarrhea. These are 
moderate values and substantially higher 
than functional scales (Pais-Ribeiro, et al., 
2008).  
In conclusion, the authors affirm 
that the Portuguese version of the QLQC-
30 has good metric properties and 
measures the same constructs the same 
way as the versions from other languages 
and cultures. Therefore, it is appropriate to 
be applied to  
people with cancer disease. 
 Since it is a general measure, there 
are several modules depending on the 
specific cancer disease. 
The Breast Cancer Module (QLQ-
BR23) is an extension of the QLQ-C30, 
specific for breast cancer (Aaronson et al, 
1993). It consists of 23 questions divided 
into four functional items (body image, 
sexual functioning, sexual enjoyment and 
future perspectives, after treatment ends) 
and four symptom items (treatment side 
effects, breast symptoms, arm symptoms 
and upset by alopecia). All items are 
presented on a 4-point Likert scale (1 = 
None; 4 = Very). All functional scales and 
symptoms items range from 0 to 100, 
obtained by specific algorithms.  Higher 
values on the functional scales correspond 
to a higher functional capacity, while in 
contrast, the highest values in the 
symptoms items, correspond to more 
symptoms, thus to a lower quality of life 
(Fayers et al, 2001). It should be noted that 
for sexual function and sexual enjoyment, 
a higher value corresponds to a better 
functioning.  
QLQ-BR23 was translated by the 
organization itself in an intercultural study 
(EORTC), from English into other 
languages (including Portuguese), using a 
process of translation and back translation. 
No studies were found with its metric 
properties in Portugal. International studies 
show good psychometric qualities, with 
good validity and consistency values. It 
has been an instrument widely applicable 
in patients with breast cancer (Fayers et 
al., 2001) and it can be used in patients 
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who are at different stages of the disease, 
covering the different types of treatment 
(surgery, chemotherapy, radiotherapy and 
hormone therapy).  
The use of EORTC QLQC-30 and 
module QLQ-BR23 in this study, implied 
an application for permission to the 
EORTC, who personally released the 




The project was presented to the 
Hospital Ethics Committee, in order to be 
authorized by the Director of 
Administration. After the approval, the 
first approach was made in the waiting 
room of the Breast Cancer Clinic, while 
the patients awaited for their oncology 
consults. Instruments were applied in an 
office of this Clinic, since the beginning of 
February until May 2012. The sample is 
composed by all women with breast cancer 
that, after the clarification of the study's 
objectives and confidentiality issues, have 
shown interest in participating. The 
evidence of cognitive and/or physical 
deficits that could hinder the completion of 




Descriptive data (means and 
standard-deviations) and parametric tests 
for means comparison (t test) were 
performed. In order to measure the 
association between our variables we used 
Pearson's correlation. Data analysis was 
performed using the Statistical Package for 
Social Sciences (SPSS), version 19.0.  
 
Results 
The diagnosis of alexithymia 
obtained from the scores of the TAS-20, 
shows that 47.1% of our sample is 
alexithymic, 31.8% are not and the 
remaining 21.1% are located in the "border 
zone". Our study has a mean value of 58.7 
which, considering the findings of Parker’s 
and Taylor’s (2000) adaptation of TAS-20 
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to the Portuguese population (M = 36.7) 
and, after performing the student's t test for 
one sample, reveals that alexithymia levels 
in our sample are significantly higher than 
the regular population (t (84) = 4.14, p 
<.01). 
Table 1 shows the values of 
Pearson’s r correlations between 
alexithymia, the functional scales and the 
symptom items from QLQC-30. 
 
Table 1 
Pearson’s R Values From The Correlations Between Alexithymia, The Functional Scales And 
The Symptom Items From QLQC-30 (N = 85). 
 Alexithymia 
Global Health Status -.529** 
Functional Scales   
Physical functioning -.431** 
Role functioning -.544** 
Emotional functioning -.600** 
Cognitive functioning -.254* 
Social functioning -.580** 
Symptom Items   
Fatigue 583** 
Nausea and vomiting  .398** 
Pain   .501** 
Dyspnea .178 
Insomnia  .440** 
Loss of appetite  .396** 
Obstipation  .211 
Diarrhea  .227* 
Financial difficulties  .770** 
                         Note: *p<.05, **p<.01. 
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The analysis of table 1 shows that 
alexithymia correlates negatively with the 
global health status of women with breast 
cancer from our sample (r = -. 529, p 
<.01). Additionally, alexithymia presents a 
significant negative correlation with all 
functional scales from the QLQC-30, 
indicating that the most alexithymic 
women have a worse perception of their 
emotional (r = - .600, p <.01), social (r = -
.580, p <.01), role (r = -.544, p <.01), 
physical (r = -.431, p <.01) and cognitive 
functions (r = -254, p <.05) during the 
disease. In terms of clinical symptoms, 
major results seem to indicate that the 
more alexithymic participants are, the 
greater the perception of fatigue and 
tiredness (r = .583, p <.01), pain (r = 501, 
p <.01), insomnia (r = .440, p <.01), 
nausea and vomiting (r = .398, p <.01), 
loss of appetite (r = .396, p <.01) and 
diarrhea (r =. 227, p <.05). 
Table 2 shows the values of 
Pearson’s r correlation between 
alexithymia, the functional scales and the 
symptom items from the Breast Cancer 
Module (QLQ-BR23).  
 
Table 2 
Pearson’s R Values From The Correlation Between Alexithymia, The Functional Scales And 
The Symptom Items From QLQ-BR23. 
 Alexithymia 
Functional Scales   
Body image -.499** 
Sexual functioning -.071 
Sexual enjoyment -.228 
Future perspective -.464** 
Symptom Items   
Treatments side effects .637** 
Breast symptoms .319** 
Arm symptoms .219* 
Upset by alopecia .451** 
                     Note: *p<.05, **p<.01. 
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Regarding the correlation between 
alexithymia, the functional scales and the 
symptom items from QLQ-BR23, table 2 
demonstrates statistically significant 
negative correlations with some scales and 
some important symptoms specific to 
breast cancer and its surgical and adjuvant 
treatments. Results indicate that the more 
alexithymic women are, the worse is their 
assessment of their body image (r = -. 499, 
p <.01) and their prospects for the future (r 
= - .464; p <.01). 
There were no statistically 
significant results in relation to sexual 
functioning. It should be noted that the 
size of our sample in these items is 
smaller, since only part of the participants 
agreed to answer questions related to their 
sexuality (N = 57).  
Regarding the symptom items, 
alexithymia has statistically significant 
positive correlations with all symptoms 
from QLQ-BR23. This indicates that the 
women in our sample that are more 
alexithymic also have a worse and a 
greater perception of the side effects from 
treatments (r = .637, p <.01), are more 
upset with alopecia (r = .451, p <.01), have 
more breast symptoms (r = .319, p <.01) 
and more complaints about the affected 
arm (r = .219, p <.05).  
 
Discussion 
Answering the first objective of 
this study that aims to (1) characterize 
alexithymia in a sample of women with 
breast cancer, our results show that our 
sample is significantly more alexithymic 
than women from the regular population 
(without the disease). These findings are 
consistent with pre-existing literature 
found by Guerra, Pinto and Mariano 
(2007) and Manna et al. (2007) in women 
with breast cancer, where the prevalence 
of alexithymia was 40 and 36%, 
respectively. They also confirm that the 
prevalence of alexithymia in this 
population appears to be more than double 
than the regular population (Guerra, Pinto 
and Mariano, 2007), estimated to be 
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between 10 and 20% (Fernandes & Tomé, 
2001). This seems to suggest that a large 
percentage of our participants have 
difficulties coping with the emotional tasks 
required during the adjustment to cancer. 
The second aim of this study is to 
(2) analyze the correlation of alexithymia 
with the quality of life perception and with 
the disease symptoms indicated on the 
Quality of Life Questionnaire (QLQC-30) 
and on the Breast Cancer Module (QLQ-
BR23), instruments by the European 
Organization for Research and Treatment 
of Cancer (EORTC) used in this study. 
Our findings suggest that the most 
alexithymic participants are the ones with 
lower perceptions about their global 
quality of life. This reinforces the negative 
effect of alexithymia in our sample, which 
is consistent with other studies that 
indicate that alexithymia may be a risk 
factor in the adjustment to breast cancer 
(Sousa, Guerra & Lencastre, 2015).  
This can be sustained when 
analyzing the relationship of alexithymia 
with different aspects of quality of life. 
Our findings seem to indicate that the 
presence of this variable is associated with 
a lower perception of different functioning 
categories, indicating that the most 
alexithymic patients have a worst 
perception of their emotional, social, role, 
physical and cognitive functions after 
diagnosis.  
In our sample, a bad expression of 
emotions and feelings seems to be related 
to the perception of physical suffering 
associated with breast cancer, because of 
the greater perception of physical side 
effects associated with the anti-cancer 
treatments, whether surgical or adjuvant. 
Also, the most alexithymic women seem to 
be more upset with alopecia and have a 
lower body-image, findings that suggest 
that this variable might have an effect on 
self-esteem related to cancer treatments.   
Our study findings seem to be 
consistent with previous literature, 
indicating that emotional difficulties may 
exacerbate and predict the severity and 
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perception of symptoms (Schlatter & 
Cameron, 2010). In our sample, the most 
alexithymic patients, also have greater 
perception of their clinical symptoms 
presence. Considering this, we might 
hypothesize that, while having emotional 
difficulties, the women with breast cancer 
who have alexithymia, might focus more 
on their physical and somatic symptoms, 
and therefore, exacerbate the perception of 
their presence. This can, in some cases, 
cause misinterpretations and 
misunderstandings about the signs of the 
disease (Taylor, Parker, Bagby, & Acklin, 
1992), which instead of a physiological 
origin, would have a psychosomatic 
nature. This hypothesis is also consistent 
with the theory of the physiological effect 
of alexithymia, in which this variable 
seems to enhance stress-related action of 
hypothalamic–pituitary–adrenocortical 
(HPA) processes and, therefore, it might 
increase the experience of autonomic and 
immune-related symptoms during 
treatments (Schlatter & Cameron, 2010). 
 
Conclusion 
This study seems to point out the 
negative impact of alexithymia in the 
quality of life of women with breast 
cancer, showing that it may be a risk factor 
in the adjustment to the disease. As a 
personality trait or a repressive coping 
mechanism of avoidance and 
maladaptation, in both cases, alexithymia 
appears to significantly impair various 
dimensions of quality of life of our 
sample. Taking that into consideration, this 
study reinforces the importance of greater 
and better expression of emotions and 
feelings during the experience of this 
disease. The repression of emotions during 
the experience of breast cancer and its 
impact on life and suffering seems to 
significantly impair the assessment made 
by women in our sample about their 
physical symptoms and the side effects of 
the disease and its treatments. This shows 
that emotional expression seems to 
constitute an important aspect for a better 
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adjustment to potentially traumatic events, 
such as breast cancer.  
Based on this study’s findings, we 
can retrieve some integrative conclusions 
that translate into implications for the 
intervention and support of cancer patients. 
We suggest that psychological 
interventions should demystify the 
negative emotional reactions to cancer, 
which are normative in the course of the 
disease, in order to reduce the coping 
styles of avoidance and emotional 
repression. This includes the need to 
deconstruct beliefs that reinforce the social 
stigma surrounding cancer that are present 
in both general population and amongst 
health professionals, concerning the 
tendency to avoid the expression of 
negative emotions.  
In a clinical context, and 
considering the example of Emotions 
Focused Therapy (EFT), the patients 
should be encouraged to reflect and 
verbalize their negative emotions, 
overcoming avoidance and repression. The 
psychologist should guide them to increase 
awareness of the sensations felt in their 
body in order to be able to experience 
them and assign words to the experience 
(focus) (Greenberg & Safran, 1987).  
We also suggest interventions 
focused on emotional regulation and 
distress tolerance, by teaching symptom 
monitoring techniques, strategies to 
identify, appoint and recognize emotions 
associated with physical discomfort, as 
well as the discussion of cognitions 
associated with those emotions. Moreover, 
important interventions that explore the 
acceptance, tolerance and validation of 
emotions should be performed, aiming to 
increase the access to positive emotions 
and to reduce the vulnerability to negative 
ones by using coping strategies, such as 
relaxation and emotion-written disclosure.  
For further investigations, it is 
important to keep studying the role of 
alexithymia in cancer, because of its 
potential influence on the underestimation 
of psychological suffering and psychiatric 
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outcome. In order to characterize 
alexithymia as a primary trait of 
personality related to cancer development 
or as an emotional state and coping 
mechanism secondary to cancer, it would 
be necessary to perform an experimental 
study, controlling the effect of this variable 
and comparing it within an experimental 
group and a control group. Also, it would 
be interesting to analyze the effect of 
alexithymia over time, allowing us to 
check if the relation between cancer and 
alexithymia would be causal or not and, 
therefore, analyze its potential influence on 
cancer development. Although this type of 
research would be very interesting, it is 
also very difficult to be performed and 
implemented within this population.  
Another suggestion for further 
investigations using this variable, would 
be the study of its impact on cancer 
progression, since recent, but very few 
studies, have suggested a relation between 
emotion supression and the immunological 
system and, therefore, with biological 
markers of illness severity, implied in 
cancer invasion and progression (Messina, 
Fogliani, Paradiso, 2011).  
References 
 
Aaronson, N. K., Ahmedzai, S., Bergman, 
B., Bullinger, M., Cull, A., Duez, 
N. J., Filiberti, A., Flechtner, H., 
Fleishman, S.B., & Haes, J.C. 
(1993). The European Organization 
for Research and Treatment of 
Cancer QLQ-C30: a quality-of-life 
instrument for use in international 
clinical trials in oncology. Journal 
of the National Cancer Institute, 
85, 365-376. 
Brenner, H., & Hakulinen, T. (2006). 
Period estimates of cancer patient 
survival are more up to date than 
complete estimates even at 
comparable levels of precision. 
Journal of Clinical Epidemiology, 
59, 570–575. 
                                                                                             ALEXITHYMIA IN BREAST CANCER      81 
   
 
ORIGINAL      
Classen, C., Koopman, C., Angell, K., & 
Spiegel, D. (1996). Coping styles 
associated with psychological 
adjustment to advanced breast 
cancer. Health Psychology, 15, 
434-437. 
Costa-Requena, G., Rodriguez, A., & 
Fernandez-Ortega, P. (2013). 
Longitudinal assessment of distress 
and quality of life in the early 
stages of breast cancer treatment. 
Scandinavian Journal of Caring 
Sciences, 27, 77-83.  
doi: 10.1111/j.1471-
6712.2012.01003.x 
Fernandes, N., & Tomé, R. (2001). 
Alexitimia. Revista Portuguesa de 
Psicossomática, 3(2), 97-111. 
Fernández-Delgado, J., López-Pedraza. 
M., Blasco J., Andradas-Aragones, 
E., Sánchez-Méndez, J., Sordo-
Miralles, G., & Reza, M. (2008). 
Satisfaction with and psychological 
impact of immediate and deferred 
breast reconstruction, Annals of 
Oncology, 19(8), 1430-1434. doi: 
10.1093/annonc/mdn153 
Fonte, J. A. (1993). Alexitimia – estudo em 
doentes com perturbações 
digestivas. Mestrado, Universidade 
do Porto, Porto.  
Grassi, L., Caruso, R., & Nanni, M. 
(2013). Somatization and somatic 
symptom presentation in cancer: a 
neglected area. International 
Review of Psychiatry, 25(1), 41 51. 
doi: 
10.3109/09540261.2012.731384 
Grassi, L., Rossi, E., Sabato, S., Cruciani, 
G., & Zambelli, M. (2004). 
Diagnostic criteria for 
psychosomatic research and 
psychosocial variables in breast 
cancer patients. Psychosomatics, 
45, 483 – 491. 
Graves, K., Schmidt, J., Bollmer, J., 
Fejfar, M., Langers, S., Blonder, 
L., & Andrykowski, M. (2005). 
Emotional expression and 
emotional recognition in breast 
                                                                                             ALEXITHYMIA IN BREAST CANCER      82 
   
 
ORIGINAL      
cancer survivors: a controlled 
comparison. Psychology and 
Health, 20(5), 579–595. 
doi:10.1080/088704404200033474
2 
Greenberg, L., & Safran, J. (1987). 
Emotion in psychotherapy: affect, 
cognition, and the process of 
change. New York: Guilford Press. 
Griiti, P., Lombardi, S., Nobile, B., 
Trappoliere, P., Gambardella, A., 
Caprio, E., & Resicato, G. (2010). 
Alexithymia and cancer-related 
fatigue: a controlled cross-sectional 
study. Tumori, 96, 131-137. 
Guerra, M.P., Pinto, A., & Mariano, S. 
(2007, October). Evaluating 
alexithymia in a breast cancer 
population. Poster session 
presented at the Fourth 
International Conference on the 
(Non)Expression of Emotions in 
Health and Disease, Tilburg 
University, The Netherlands.  
Holland, K., & Holahan, C. (2003). The 
relation of social support and 
coping to positive adaptation to 
breast cancer. Psychology and 
Health, 18(1), 15–29.  
doi:10.1080/0887044031000080656 
Iwamitsu, Y., Shimoda, K., Abe, H., Tani, 
T., Kodama, M., & Okawa, M. 
(2003). Differences in emotional 
distress between breast tumor 
patients with emotional inhibition 
and those with emotional 
expression. Psychiatry and Clinical 
Neurosciences, 57, 289-294. 
Knobf, M. (2007). Psychosocial responses 
in breast cancer survivors. 
Seminars in Oncology Nursing, 23, 
71-83. 
Lieberman, M., & Goldstein, B. (2006). 
Not all negative emotions are 
equal: the role of emotional 
expression in online support groups 
for women with breast cancer. 
Psycho-Oncology, 15, 160–168. 
                                                                                             ALEXITHYMIA IN BREAST CANCER      83 
   
 
ORIGINAL      
Lopes, H., Ribeiro, J., & Leal, I. (1999). 
Estudos sobre qualidade de vida em 
mulheres submetidas a 
histerectomia ou anexectomia para 
tratamento de cancro do útero ou 
ovário. Analise Psicológica, XVII, 
483-497. 
Manna, G., Foddai, E., Maggio, M., Pace, 
F., Colucci, G., Gebbia, N., & 
Russo, A. (2007). Emotional 
expression and coping style in 
female breast cancer. Annals of 
Oncology, 18, 77-80. 
Mantani, T., Saeki, T., Inoue, S., 
Okamura, H., Daino, M., Kataoka, 
T., & Yamawaki, S. (2007). 
Factors related to anxiety and 
depression in women with breast 
cancer and their husbands: role of 
alexithymia and family 
functioning. Support Care Cancer, 
15, 859-868. 
Messina, A., Fogliani, A., & Paradiso, S. 
(2011). Alexithymia in oncologic 
disease: association with cancer 
invasion and hemoglobin levels. 
Annals of Clinical Psychiatry, 
23(2), 125–130. 
Montarezi, A. (2007). Health-related 
quality of life in breast cancer 
patients: a bibliographic review of 
the literature from 1974 to 2007. 
Journal of Experimental & Clinical 
Cancer Research, 27(32), 1-31. 
doi: 10.1186/1756-9966-27-32 
Moos, R., & Schaefer, J. (1989). The 
Crisis of Physical Illness: an 
overview and conceptual approach. 
In R. Moos (ed.). Coping with 
physical illness (pp.13-25). New 
York: Plenum Medical Book 
Company. 
Pimentel, F. (2006). Qualidade de vida e 
oncologia. Coimbra: Edições 
Almedina 
Pinto, C., & Ribeiro, J. (2006). A 
qualidade de vida dos 
sobreviventes de cancro. Revista 
Portuguesa de Saúde Pública, 
24(1), 37-56. 
                                                                                             ALEXITHYMIA IN BREAST CANCER      84 
   
 
ORIGINAL      
Porcelli, P., Tulipani, C., Maiello, E., 
Cilenti, G., & Todarello, O. (2007). 
Alexithymia, coping, and illness 
behavior correlates of pain 
experience in cancer patients. 
Psychooncology, 16, 644 – 650. 
Prazeres, N., Parker, P., & Taylor, J. 
(2000). Adaptação portuguesa da 
Escala de Alexitimia de Toronto de 
20 itens (TAS-20). Revista 
Iberoamericana de Diagnóstico e 
Avaliação Psicológica, 9, 9-21. 
Rebelo, V., Rolim, L., Carqueja, E., & 
Ferreira, S. (2007). Avaliação da 
qualidade de vida em mulheres 
com cancro de mama: um estudo 
exploratório com 60 mulheres 
portuguesas. Psicologia, Saúde & 
Doenças, 8, 13-32. 
Ribeiro, J., Pinto, C., & Santos, C. (2008). 
Validation study of the Portuguese 
version of the QLC-C30-V.3. 
Psicologia, Saúde & Doenças, 
9(1), 89-102. 
Safarinejad, M., Shafi, N., & Safarinejad, 
S. (2013). Quality of life and 
sexual functioning in young 
women with early-stage breast 
cancer 1 year after lumpectomy. 
Psycho-Oncology, 22, 1242-1248. 
doi: 10.1002/pon.3130 
Schlatter, M., & Cameron, L. (2010). 
Emotional suppression tendencies 
as predictors of symptoms, mood, 
and coping appraisals during AC 
chemotherapy for breast cancer 
treatment. Annals of Behavioral 
Medicine, 40, 15–29. doi: 
10.1007/s12160-010-9204-6 
Sifneos, P. (1991). Affect, emotional 
conflict, and deficit: an overview. 
Psychotherapy and 
Psychosomatics, 56, 116-122.  
Silva, S., Bettencourt, D., Moreira, H., & 
Canavarro, M. C. (2011). 
Qualidade de vida de mulheres com 
cancro da mama nas diversas fases 
da doença: o papel de variáveis 
sociodemográficas, clinicas e das 
                                                                                             ALEXITHYMIA IN BREAST CANCER      85 
   
 
ORIGINAL      
estratégias de coping enquanto 
fatores de risco/proteção. Revista 
Portuguesa de Saúde Publica, 29, 
64-67.  
Shibata, M., Ninomiua, T., Jensen, M., 
Anno, K., Yonemoto, K., Makino, 
S., & Hoso, M. (2014). 
Alexithymia is associated with 
greater risk of chronic pain and 
negative affect and with lower life 
satisfaction in a general population: 
the Hisayama study. PLoS ONE, 9, 
3, 1-8. doi: 
10.1371/journal.pone.0090984 
Sousa, H., Guerra, M., & Lencastre, L. 
(2015). Preditores da qualidade de 
vida numa amostra de mulheres 
com cancro de mama, Análise 
Psicológica, 33 (1), pp. 39-53. 
doi: 10.14417/ap.832 
Taylor, G., Parker, J., Bagby, M., & 
Acklin, M. (1992). Alexithymia 
and somatic complaints in 
psychiatric out-patients. Journal of 
Psychosomatic Research, 36 (5), 
417-424. 
Vazquez, I., Rodriguez, C., & Álvarez, M. 
(2003). Manual de psicologia de la 
salud. Madrid: Ediciones Pirâmid. 
Vries, A., Forni, V., Voellinger, R., & 
Stiefel, F. (2012). Alexithymia in 
cancer patients: review of the 
literature. Psychotherapy and 
Psychosomatics, 81, 79–86.  
doi: 10.1159/000330888 
Watson, M., Greer, S., & Rowden, L. 
(1991). Relationship between 
emotional control, adjustment to 
cancer and depression and anxiety 
in breast cancer patients. 
Psychological Medicine, 21, 51-57. 
Yasaman Ashkhaneh, Y., Mollazadeh, J., 
Aflakseir, A., Goudarzi, M., & 
Shandiz, F. (2015). Study of 
difficulty in emotion regulation as a 
predictor of incidence and severity 
of nausea and vomiting in breast 
cancer patients. Fundamentals of 
Mental Health, 17(3), 123-8
How to cite this Article: Sousa,H., Guerra, M., & Lencastre, L. (2016). “Emotions words can’t translate”: Studying alexithymia in a 
sample of women with breast cancer. International Journal of Psychology and Neuroscience, 2(4), 61-85.                        
Recived: 11/11/2015;   Revised: 12/12/2015;  Accepted: 19/01/2016;  Published online:  9/05/2016                           ISSN  2183-5829 
 
 
